1. Home
  2. CADL vs BGH Comparison

CADL vs BGH Comparison

Compare CADL & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$11.94

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Barings Global Short Duration High Yield Fund of Beneficial Interests

BGH

Barings Global Short Duration High Yield Fund of Beneficial Interests

HOLD

Current Price

$13.53

Market Cap

278.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
BGH
Founded
1999
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
278.7M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
CADL
BGH
Price
$11.94
$13.53
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
1.1M
67.5K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
10.06%
EPS Growth
58.62
N/A
EPS
N/A
N/A
Revenue
$125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$13.19
52 Week High
$14.00
$16.65

Technical Indicators

Market Signals
Indicator
CADL
BGH
Relative Strength Index (RSI) 48.82 31.10
Support Level $9.40 N/A
Resistance Level $14.00 $14.35
Average True Range (ATR) 0.71 0.14
MACD -0.18 -0.04
Stochastic Oscillator 46.56 3.87

Price Performance

Historical Comparison
CADL
BGH

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests

Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.

Share on Social Networks: